托法替布口服剂量递减治疗全秃一例的疗效
Effectiveness of Oral Tofacitinib Dose Tapering in a Case of Alopecia Areata Universalis.
作者信息
Esteves Mariana, Lopes Sofia, Azevedo Filomena, Pedrosa Ana
机构信息
Serviço de Dermatologia e Venereologia, Centro Hospitalar Universitário de São João EPE, Porto, Portugal.
Faculdade de Medicina, Universidade do Porto, Porto, Portugal.
出版信息
Skin Appendage Disord. 2021 Jan;7(1):36-40. doi: 10.1159/000510673. Epub 2020 Sep 30.
INTRODUCTION
Alopecia areata (AA) is a form of nonscarring alopecia and one of the most common autoimmune disorders. Persistent or severe variants lead to potential disfigurement and are associated with a significant negative impact on the patient's quality of life.
CASE PRESENTATION
A 51-year-old female patient presenting with refractory alopecia universalis was successfully treated with oral tofacitinib. Recurrence was not observed following 17 months of therapy.
DISCUSSION/CONCLUSION: None of the currently employed therapies for AA are reliably effective nor are they approved for the disease. In this setting, Janus kinase inhibitors emerge as a promising novel treatment, as increasing evidence supports their effectiveness in AA.
引言
斑秃（AA）是一种非瘢痕性脱发，也是最常见的自身免疫性疾病之一。持续性或严重型斑秃会导致潜在的容貌损毁，并对患者的生活质量产生重大负面影响。
病例报告
一名51岁的女性患者患有难治性全秃，口服托法替布治疗成功。治疗17个月后未观察到复发。
讨论/结论：目前用于治疗斑秃的疗法均未被证实可靠有效，也未获该疾病的治疗许可。在这种情况下，随着越来越多的证据支持其在斑秃治疗中的有效性，Janus激酶抑制剂成为一种有前景的新型治疗方法。
Zotero 插件